Engineered CXCL12 alpha locked dimer polypeptide
AssigneesThe Medical College of Wisconsin Research Foundation, Inc., The Rockefeller University
InventorsBrian F. Volkman, Christopher T. Veldkamp, Francis C. Peterson, Thomas Sakmar, Christoph H. Seibert
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel CXCL12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
Claims7
A method of treating blood cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12α2 locked dimer polypeptide, wherein the blood cancer cells express CXCR4.
A method of treating leukemia in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12α2 locked dimer polypeptide, wherein the leukemia cells express CXCR4.
A method of inhibiting migration of cancer cells in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12α2 locked dimer polypeptide, wherein the cancer cells express CXCR4.
A method of inhibiting migration of leukemia cells in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a CXCL12α2 locked dimer polypeptide, wherein the leukemia cells express CXCR4.
Dependencies are inferred from the claim text.